Ewha Med J.  2021 Jul;44(3):93-96. 10.12771/emj.2021.44.3.93.

Differentiating between Intestinal Tuberculosis and Crohn’s Disease May Be Complicated by Multidrug-resistant Mycobacterium tuberculosis

  • 1Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea


Differentiating between intestinal tuberculosis (ITB) and Crohn’s disease (CD) remains a challenge for gastroenterologists. In Asia, where the prevalence of tuberculosis is relatively high and the incidence of CD is rapidly increasing, this issue is crucial. Here we report a case that was initially misdiagnosed as CD, subsequently showed no response to empirical first-line anti-tuberculosis medication, and was finally diagnosed with multidrug-resistant ITB. This case reminds physicians that multidrug-resistant ITB may complicate distinguishing between ITB and CD


Crohn’s disease; Gastrointestinal tuberculosis; Multidrug-resistant tuberculosis


  • Fig. 1 Serial colonoscopy findings. (A) Initial colonoscopy performed in another hospital reveals multiple transverse ulcers in the ascending colon. (B) Follow-up colonoscopy performed 11 weeks after commencement of the first anti-tuberculosis therapy still shows multiple transverse ulcers in the ascending colon. (C) Follow-up colonoscopy performed 25 weeks after commencement of the first anti-tuberculosis therapy still shows multiple transverse ulcers in the ascending colon. (D) Follow-up colonoscopy performed 28 weeks after therapy for multidrug-resistant intestinal tuberculosis shows only scarring and no active ulcers. A written informed consent for publication and use of medical data and images was obtained from the patient.

Cited by  1 articles

Is Multidrug-resistant Extrapulmonary Tuberculosis Important? If So, What Is Our Strategy?
Seong-Eun Kim
Ewha Med J. 2021;44(4):148-149.    doi: 10.12771/emj.2021.44.4.148.


1. Ham NS, Myung SJ. 2021; Endoscopic molecular imaging in inflammatory bowel disease. Intest Res. 19:33–44. DOI: 10.5217/ir.2019.09175. PMID: 32299156. PMCID: PMC7873406.
2. Ye BD, Yang SK, Kim D, Shim TS, Kim SH, Kim MN, et al. 2012; Diagnostic sensitivity of culture and drug resistance patterns in Korean patients with intestinal tuberculosis. Int J Tuberc Lung Dis. 16:799–804. DOI: 10.5588/ijtld.11.0252. PMID: 22508109.
3. Samant H, Desai D, Abraham P, Joshi A, Gupta T, Rodrigues C, et al. 2014; Acid-fast bacilli culture positivity and drug resistance in abdominal tuberculosis in Mumbai, India. Indian J Gastroenterol. 33:414–419. DOI: 10.1007/s12664-014-0467-x. PMID: 24927950.
4. Park SH, Kim YJ, Rhee KH, Kim YH, Hong SN, Kim KH, et al. 2019; A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015. J Crohns Colitis. 13:1410–1417. DOI: 10.1093/ecco-jcc/jjz081. PMID: 30989166.
5. GBD 2017 Inflammatory Bowel Disease Collaborators. 2020; The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 5:17–30. DOI: 10.1016/S2468-1253(19)30333-4. PMID: 31648971. PMCID: PMC7026709.
6. Park SH, Yang SK, Yang DH, Kim KJ, Yoon SM, Choe JW, et al. 2009; Prospective randomized trial of six-month versus nine-month therapy for intestinal tuberculosis. Antimicrob Agents Chemother. 53:4167–4171. DOI: 10.1128/AAC.00874-09. PMID: 19667282. PMCID: PMC2764179.
7. Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, et al. 2019; Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res. 17:285–310. DOI: 10.5217/ir.2019.00026. PMID: 31146509. PMCID: PMC6667368.
8. Lee YJ, Yang SK, Byeon JS, Myung SJ, Chang HS, Hong SS, et al. 2006; Analysis of colonoscopic findings in the differential diagnosis between intestinal tuberculosis and Crohn's disease. Endoscopy. 38:592–597. DOI: 10.1055/s-2006-924996. PMID: 16673312.
9. Kim BJ, Choi YS, Jang BI, Park YS, Kim WH, Kim YS, et al. 2011; Prospective evaluation of the clinical utility of interferon-γ assay in the differential diagnosis of intestinal tuberculosis and Crohn's disease. Inflamm Bowel Dis. 17:1308–1313. DOI: 10.1002/ibd.21490.
10. Bae JH, Park SH, Ye BD, Kim SO, Cho YK, Youn EJ, et al. 2017; Development and validation of a novel prediction model for differential diagnosis between Crohn's disease and intestinal tuberculosis. Inflamm Bowel Dis. 23:1614–1623. DOI: 10.1097/MIB.0000000000001162. PMID: 21053248.
11. Limsrivilai J, Pausawasdi N. 2021; Intestinal tuberculosis or Crohn's disease: a review of the diagnostic models designed to differentiate between these two gastrointestinal diseases. Intest Res. 19:21–32. DOI: 10.5217/ir.2019.09142.
12. Alrajhi S, Germain P, Martel M, Lakatos P, Bessissow T, Al-Taweel T, et al. 2020; Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease. Intest Res. 18:306–314. DOI: 10.5217/ir.2019.00116. PMID: 32182640. PMCID: PMC7385575.
13. Ooi CJ, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, et al. 2016; Asia Pacific Consensus Statements on Crohn's disease. Part 1: Definition, diagnosis, and epidemiology: (Asia Pacific Crohn's Disease Consensus--Part 1). J Gastroenterol Hepatol. 31:45–55. DOI: 10.1111/jgh.12956.
14. Seo H, Lee S, So H, Kim D, Kim SO, Soh JS, et al. 2017; Temporal trends in the misdiagnosis rates between Crohn's disease and intestinal tuberculosis. World J Gastroenterol. 23:6306–6314. DOI: 10.3748/wjg.v23.i34.6306. PMID: 28974897. PMCID: PMC5603497.
15. Lee YJ, Yang SK, Myung SJ, Byeon JS, Park IG, Kim JS, et al. 2004; The usefulness of colonoscopic biopsy in the diagnosis of intestinal tuberculosis and pattern of concomitant extra-intestinal tuberculosis. Korean J Gastroenterol. 44:153–159. PMID: 15385724.
Full Text Links
  • EMJ
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr